Skip to main content

Table 3 Number and proportion of patients with at least one adverse event

From: Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

Adverse events Kibaha (n = 80) Ujiji (n = 88) Mkuzi (n = 88) Mlimba (n = 88) Total (n = 344)
Cough 0 (0%) 12 (13.6%) 31 (35.2%) 1 (1.1%) 44 (12.8%)
Abdominal pain 2 (2.5%) 1 (1.1%) 12 (13.6%) 0 (0%) 15 (4.4%)
Vomiting 3 (3.8%) 0 (0%) 9 (10.2%) 1 (1.1%) 13 (3.8%)
Diarrhoea 0 (0%) 0 (0%) 3 (3.4%) 1 (1.1%) 4 (1.2%)
Headache 1 (1.3%) 0 (0%) 1 (1.1%) 0 (0%) 2 (0.6%)
Others 0 (0%) 10 (11.4%) 5 (3.4%) 3 (3.4%) 18 (5.2%)
Total 6 (7.5%) 23 (26.1%) 61 (69.3%) 6 (6.8%) 96 (27.9%)